Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted Therapies - Episode 6
Optimal Timing for Introducing Afami-Cel Therapy in the Treatment Journey
A panelist discusses how afamitresgene autoleucel (afami-cel) therapy should be considered early in the treatment journey after initial standard of care when patients still have good performance status and adequate organ function to maximize the potential benefit of this cellular therapy approach.
Video Player is loading.
Video content above is prompted by the following:
- At what point in a patient’s treatment journey should afami-cel therapy be introduced?
Related Content:
